Crestwood Advisors Group LLC Invests $41,000 in C4 Therapeutics, Inc. $CCCC

Crestwood Advisors Group LLC acquired a new position in C4 Therapeutics, Inc. (NASDAQ:CCCC) during the 2nd quarter, Holdings Channel reports. The fund acquired 29,000 shares of the company’s stock, valued at approximately $41,000.

Other large investors have also recently added to or reduced their stakes in the company. Brookstone Capital Management acquired a new position in C4 Therapeutics during the second quarter worth about $42,000. Acadian Asset Management LLC acquired a new stake in shares of C4 Therapeutics in the first quarter valued at approximately $43,000. R Squared Ltd purchased a new position in shares of C4 Therapeutics during the 2nd quarter worth approximately $44,000. XTX Topco Ltd acquired a new position in shares of C4 Therapeutics during the 1st quarter worth approximately $64,000. Finally, Deutsche Bank AG purchased a new stake in C4 Therapeutics in the 1st quarter valued at approximately $74,000. 78.81% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on CCCC. Wells Fargo & Company raised their price target on C4 Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 23rd. Zacks Research cut C4 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Wednesday, October 8th. Stephens reaffirmed an “overweight” rating and set a $6.00 price target on shares of C4 Therapeutics in a research note on Monday, September 22nd. Finally, Guggenheim initiated coverage on shares of C4 Therapeutics in a research report on Wednesday, September 3rd. They issued a “buy” rating and a $8.00 price objective for the company. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.50.

C4 Therapeutics Price Performance

CCCC opened at $2.34 on Friday. C4 Therapeutics, Inc. has a 12 month low of $1.09 and a 12 month high of $6.20. The business has a 50-day moving average of $2.52 and a two-hundred day moving average of $2.08. The stock has a market capitalization of $166.54 million, a price-to-earnings ratio of -1.40 and a beta of 2.95.

C4 Therapeutics (NASDAQ:CCCC) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.03. C4 Therapeutics had a negative net margin of 395.51% and a negative return on equity of 61.05%. The business had revenue of $11.23 million for the quarter, compared to analyst estimates of $6.28 million. Equities research analysts anticipate that C4 Therapeutics, Inc. will post -1.52 earnings per share for the current year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.